Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
EBioMedicine. 2021 May;67:103354. doi: 10.1016/j.ebiom.2021.103354. Epub 2021 Apr 25.
While initial approaches to adoptive T cell therapy relied on the identification and expansion of rare tumour-reactive T cells, genetic engineering has transformed cancer immunotherapy by enabling the modification of primary T cells to increase their therapeutic potential. Specifically, gene editing technologies have been utilized to create T cell populations with improved responses to antigens, lower rates of exhaustion, and potential for use in allogeneic applications. In this review, we provide an overview of T cell therapy gene editing strategies and the delivery technologies utilized to genetically engineer T cells. We also discuss recent investigations and clinical trials that have utilized gene editing to enhance the efficacy of T cells and broaden the application of cancer immunotherapies.
虽然最初采用过继性 T 细胞疗法依赖于识别和扩增罕见的肿瘤反应性 T 细胞，但基因工程通过修饰原代 T 细胞以提高其治疗潜力，从而彻底改变了癌症免疫疗法。具体而言，基因编辑技术已被用于创建对抗原具有更好反应性、更低衰竭率且可用于同种异体应用的 T 细胞群体。在这篇综述中，我们提供了 T 细胞治疗基因编辑策略的概述以及用于基因工程 T 细胞的递送技术。我们还讨论了最近利用基因编辑来提高 T 细胞疗效并拓宽癌症免疫疗法应用的研究和临床试验。
